GSK plc Form 6-K: Report of foreign private issuer
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2024-04-17: Form 6-K; Period of report 2024-04-17; Description GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS; Document a8530k.htm.
- 2024-04-16: Form 6-K; Period of report 2024-04-16; Description AMENDMENT - DIRECTOR/PDMR SHAREHOLDING; Document a8442k.htm.
- 2024-04-16: Form 6-K; Period of report 2024-04-16; Description FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE; Document a7019k.htm.
- 2024-04-15: Form 6-K; Period of report 2024-04-15; Description DIRECTOR/PDMR SHAREHOLDING; Document a6kcovergsk.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2024-04-17 | 6-K | 2024-04-17 | GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS | a8530k.htm |
| 2024-04-16 | 6-K | 2024-04-16 | AMENDMENT - DIRECTOR/PDMR SHAREHOLDING | a8442k.htm |
| 2024-04-16 | 6-K | 2024-04-16 | FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE | a7019k.htm |
| 2024-04-15 | 6-K | 2024-04-15 | DIRECTOR/PDMR SHAREHOLDING | a6kcovergsk.htm |
| 2024-04-04 | 6-K/A | 2024-04-04 | REPLACEMENT - TOTAL VOTING RIGHTS | a3616j.htm |
| 2024-04-02 | 6-K | 2024-04-02 | TOTAL VOTING RIGHTS | a9553i.htm |
| 2024-03-26 | 6-K | 2024-03-26 | DIRECTOR/PDMR SHAREHOLDING | a3422i.htm |
| 2024-03-25 | 6-K | 2024-03-25 | NOTICE OF AGM | a1909i.htm |
| 2024-03-22 | 6-K | 2024-03-22 | TRANSFER OF TREASURY SHARES | a0292i.htm |
| 2024-03-22 | 6-K | 2024-03-22 | DIRECTOR/PDMR SHAREHOLDING | a0257i.htm |
| 2024-03-18 | 6-K | 2024-03-18 | NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER | a2253h.htm |
| 2024-03-13 | 6-K | 2024-03-13 | DIRECTOR/PDMR SHAREHOLDING | gsk-7500g.htm |
| 2024-03-08 | 6-K | 2024-03-08 | BOARD COMMITTEE CHANGE | a2302g.htm |
| 2024-03-07 | 6-K | 2024-03-07 | GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS | a9252f.htm |
| 2024-03-06 | 6-K | 2024-03-06 | VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED | a8792f.htm |
| 2024-03-05 | 6-K | 2024-03-05 | GSK ANNUAL REPORT 2023 ON FORM 20 F | a7087f.htm |
| 2024-03-05 | 6-K | 2024-03-05 | NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING | a5339f.htm |
| 2024-03-01 | 6-K | 2024-03-01 | TOTAL VOTING RIGHTS | a2955f.htm |
| 2024-03-01 | 6-K | 2024-03-01 | GSK PUBLISHES ANNUAL REPORT 2023 | a2983f.htm |
| 2024-02-29 | 6-K | 2024-02-29 | DIRECTORATE CHANGE | a866e.htm |
| 2024-02-29 | 6-K | 2024-02-29 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a8759e.htm |
| 2024-02-26 | 6-K | 2024-02-26 | DIRECTOR/PDMR SHAREHOLDING | a4840e.htm |
| 2024-02-26 | 6-K | 2024-02-26 | GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS | a3316e.htm |
| 2024-02-22 | 6-K | 2024-02-22 | DIRECTOR/PDMR SHAREHOLDING | a1650egsk.htm |
| 2024-02-21 | 6-K | 2024-02-21 | VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED | a8994d.htm |
| 2024-02-20 | 6-K | 2024-02-20 | DIRECTOR/PDMR SHAREHOLDING | a6kcovergsk-6610d.htm |
| 2024-02-15 | 6-K | 2024-02-15 | DIRECTOR/PDMR SHAREHOLDING | a3369d.htm |
| 2024-02-15 | 6-K | 2024-02-15 | GSK COMPLETES ACQUISITION OF AIOLOS BIO | a1862d.htm |
| 2024-02-13 | 6-K | 2024-02-13 | DIRECTOR/PDMR SHAREHOLDING | a0181d.htm |
| 2024-02-13 | 6-K | 2024-02-13 | DIRECTOR/PDMR SHAREHOLDING | a0224d.htm |
| 2024-02-13 | 6-K | 2024-02-13 | DIRECTOR/PDMR SHAREHOLDING | a0165d.htm |
| 2024-02-12 | 6-K | 2024-02-12 | DIRECTOR/PDMR SHAREHOLDING | a8663c.htm |
| 2024-02-12 | 6-K | 2024-02-12 | DIRECTOR/PDMR SHAREHOLDING | a8661c.htm |
| 2024-02-12 | 6-K | 2024-02-12 | DIRECTOR/PDMR SHAREHOLDING | a8653c.htm |
| 2024-02-12 | 6-K | 2024-02-12 | US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN | a7138c.htm |
| 2024-02-06 | 6-K | 2024-02-06 | FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK | a0969c.htm |
| 2024-02-06 | 6-K | 2024-02-06 | SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED | a1543c.htm |
| 2024-02-06 | 6-K | 2024-02-06 | GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA | a0849c.htm |
| 2024-02-01 | 6-K | 2024-02-01 | DIRECTOR/PDMR SHAREHOLDING | a7495b.htm |
| 2024-02-01 | 6-K | 2024-02-01 | TOTAL VOTING RIGHTS | a7513b.htm |
| 2024-02-01 | 6-K | 2024-02-01 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | a6kcovergsk.htm |
| 2024-01-31 | 6-K | 2024-01-31 | FINAL RESULTS | a4323b-edgar.htm |
| 2024-01-29 | 6-K | 2024-01-29 | EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK | a1224bgskedgar.htm |
| 2024-01-29 | 6-K | 2024-01-29 | EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU | a1191bgskedgar.htm |
| 2024-01-19 | 6-K | 2024-01-19 | DIRECTOR/PDMR SHAREHOLDING | a3479a.htm |
| 2024-01-17 | 6-K | 2024-01-16 | CURRENT REPORT | gsk-6k_011624.htm |
| 2024-01-17 | 6-K | 2024-01-17 | DIRECTOR/PDMR SHAREHOLDING | a0494a.htm |
| 2024-01-17 | 6-K | 2024-01-17 | GSK COMPLETES SALE OF SHARES IN HALEON PLC | a9246z.htm |
| 2024-01-16 | 6-K | 2024-01-16 | DIRECTOR/PDMR SHAREHOLDING | a8636z.htm |
| 2024-01-10 | 6-K | 2024-01-10 | NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA | a1393z.htm |
| 2024-01-09 | 6-K | 2024-01-09 | GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO | a0755z.htm |
| 2024-01-02 | 6-K | 2024-01-02 | TOTAL VOTING RIGHTS | a3780y.htm |